Combination Of Direct Acting Antiviral Agents And Ribavirin For Treating Hcv Patients

Patent No. EP2968302 (titled "Combination Of Direct Acting Antiviral Agents And Ribavirin For Treating Hcv Patients") was filed by Abbvie on Mar 14, 2014. The application was issued on Feb 13, 2019.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKJun 6, 2018TER MEER STEINMEISTER & PARTNER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2968302

ABBVIE
Application Number
EP14725812A
Filing Date
Mar 14, 2014
Status
Revoked
Sep 2, 2020
Publication Date
Feb 13, 2019